{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:13:39Z","timestamp":1761844419159},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Lebanese National Council for Scientific Research organization","award":["CCF11232012_00018"],"award-info":[{"award-number":["CCF11232012_00018"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental and Molecular Pathology"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.yexmp.2014.09.008","type":"journal-article","created":{"date-parts":[[2014,9,16]],"date-time":"2014-09-16T08:18:15Z","timestamp":1410855495000},"page":"315-320","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Comparing BRAF mutation status in matched primary and metastatic cutaneous melanomas: Implications on optimized targeted therapy"],"prefix":"10.1016","volume":"97","author":[{"given":"Maya","family":"Saroufim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert H.","family":"Habib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Gerges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jad","family":"Saab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asif","family":"Loya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samir S.","family":"Amr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salwa","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Satti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Oberkanins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim","family":"Khalifeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yexmp.2014.09.008_bb0005","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1358\/dot.2012.48.2.1745274","article-title":"Vemurafenib: the road to personalized medicine in melanoma","volume":"48","author":"Amaria","year":"2012","journal-title":"Drugs Today (Barc.)"},{"key":"10.1016\/j.yexmp.2014.09.008_bb0010","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ccr.2010.10.029","article-title":"Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A","volume":"19","author":"Arozarena","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.yexmp.2014.09.008_bb0015","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1038\/sj.onc.1211003","article-title":"Mutant B-RAF mediates resistance to anoikis via Bad and Bim","volume":"27","author":"Boisvert-Adamo","year":"2008","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.yexmp.2014.09.008_bb0020","first-page":"1691","article-title":"Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients Ann","volume":"24","author":"Boussemart","year":"2013","journal-title":"Oncol."},{"key":"10.1016\/j.yexmp.2014.09.008_bb0025","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/PAS.0b013e318271249e","article-title":"Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions","volume":"37","author":"Busam","year":"2012","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.yexmp.2014.09.008_bb0030","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00401-011-0841-z","article-title":"Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody","volume":"122","author":"Capper","year":"2011","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.yexmp.2014.09.008_bb0035","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1755-148X.2008.00491.x","article-title":"Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival","volume":"21","author":"Cartlidge","year":"2008","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.yexmp.2014.09.008_bb0040","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yexmp.2014.09.008_bb0045","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1200\/JCO.2011.41.2452","article-title":"BRAF\/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma","volume":"30","author":"Colombino","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.yexmp.2014.09.008_bb0050","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMoa050092","article-title":"Distinct sets of genetic alterations in melanoma","volume":"353","author":"Curtin","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yexmp.2014.09.008_bb0055","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.yexmp.2014.09.008_bb0060","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/01.cmr.0000232300.22032.86","article-title":"NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing","volume":"16","author":"Edlundh-Rose","year":"2006","journal-title":"Melanoma Res."},{"key":"10.1016\/j.yexmp.2014.09.008_bb0065","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/CCO.0b013e3282f5271c","article-title":"The MAPK pathway in melanoma","volume":"20","author":"Fecher","year":"2008","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.yexmp.2014.09.008_bb0070","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.yexmp.2014.09.008_bb0075","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J. Clin."},{"issue":"4","key":"10.1016\/j.yexmp.2014.09.008_bb0080","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/DAD.0b013e31826db181","article-title":"Predictors of BRAF mutation in melanocytic nevi: analysis across regions with different UV radiation exposure Am","volume":"35","author":"Karram","year":"2013","journal-title":"J. Dermatopathol."},{"key":"10.1016\/j.yexmp.2014.09.008_bb0085","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/PAS.0b013e31802b3488","article-title":"Genetically heterogeneous and clonally unrelated metastases may arise in patients with cutaneous melanoma","volume":"31","author":"Katona","year":"2007","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.yexmp.2014.09.008_bb0090","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/PAS.0b013e31826485c0","article-title":"Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma","volume":"37","author":"Long","year":"2012","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.yexmp.2014.09.008_bb0095","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/ng1768","article-title":"Genetic clonal diversity predicts progression to esophageal adenocarcinoma","volume":"38","author":"Maley","year":"2006","journal-title":"Nat. Genet."},{"key":"10.1016\/j.yexmp.2014.09.008_bb0100","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/PAS.0000000000000136","article-title":"Intrapatient homogeneity of BRAFV600E expression in melanoma","volume":"38","author":"Menzies","year":"2013","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.yexmp.2014.09.008_bb0105","first-page":"6483","article-title":"NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression","volume":"9","author":"Omholt","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.yexmp.2014.09.008_bb0110","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0248-4900(01)01125-X","article-title":"The Raf\/MEK\/ERK pathway: new concepts of activation","volume":"93","author":"Peyssonnaux","year":"2001","journal-title":"Biol. Cell."},{"key":"10.1016\/j.yexmp.2014.09.008_bb0115","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/ng1054","article-title":"High frequency of BRAF mutations in nevi","volume":"33","author":"Pollock","year":"2003","journal-title":"Nat. Genet."},{"key":"10.1016\/j.yexmp.2014.09.008_bb0120","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/DAD.0b013e318293f355","article-title":"BRAF analysis on a spectrum of melanocytic neoplasms: an epidemiological study across differing UV regions","volume":"36","author":"Saroufim","year":"2014","journal-title":"Am. J. Dermatopathol."},{"key":"10.1016\/j.yexmp.2014.09.008_bb0125","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/jdv.12148","article-title":"BRAF mutational epidemiology in dysplastic nevi: does different solar UV radiation exposure matter?","volume":"28","author":"Saroufim","year":"2014","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.yexmp.2014.09.008_bb0130","doi-asserted-by":"crossref","first-page":"6670","DOI":"10.1158\/0008-5472.CAN-09-4471","article-title":"Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells","volume":"70","author":"Shao","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.yexmp.2014.09.008_bb0135","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1158\/1078-0432.CCR-1169-3","article-title":"Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas","volume":"10","author":"Shinozaki","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.yexmp.2014.09.008_bb0140","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/ijc.10978","article-title":"A pivotal role for ERK in the oncogenic behaviour of malignant melanoma?","volume":"104","author":"Smalley","year":"2003","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.yexmp.2014.09.008_bb0145","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1111\/j.1349-7006.2008.00782.x","article-title":"Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib","volume":"99","author":"Taniguchi","year":"2008","journal-title":"Cancer Sci."},{"key":"10.1016\/j.yexmp.2014.09.008_bb0150","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S0092-8674(04)00215-6","article-title":"Mechanism of activation of the RAF\u2013ERK signaling pathway by oncogenic mutations of B-RAF","volume":"116","author":"Wan","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.yexmp.2014.09.008_bb0155","doi-asserted-by":"crossref","first-page":"e29336","DOI":"10.1371\/journal.pone.0029336","article-title":"Intra- and inter-tumor heterogeneity of BRAF(V600E) mutations in primary and metastatic melanoma","volume":"7","author":"Yancovitz","year":"2012","journal-title":"PLoS One"}],"container-title":["Experimental and Molecular Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001448001400149X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001448001400149X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,29]],"date-time":"2018-09-29T15:24:55Z","timestamp":1538234695000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001448001400149X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S001448001400149X"],"URL":"https:\/\/doi.org\/10.1016\/j.yexmp.2014.09.008","relation":{},"ISSN":["0014-4800"],"issn-type":[{"value":"0014-4800","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparing BRAF mutation status in matched primary and metastatic cutaneous melanomas: Implications on optimized targeted therapy","name":"articletitle","label":"Article Title"},{"value":"Experimental and Molecular Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yexmp.2014.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}